A Phase 3 interventional study of Precedex and Midazolam in Mechanically Ventilated, Critically Ill Children, sponsored by Douglas Fraser. Recruiting at 1 site in Canada. Open to participants aged 1 Month to 17 Years. Per ClinicalTrials.gov, last updated 2023-12-11.
Sponsored by Douglas Fraser · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies testing dexmedetomidine in Delirium — 14 open to participants now, 17 under way, 4 of them phase 3. Dexmedetomidine · Delirium.
Among the 78 studies testing dexmedetomidine in Delirium, this one is the 35th largest by planned enrollment, is one of 7 that started in 2021, is one of 11 in phase 3, reaches primary completion later than 0 of the 16 other live ones, and was the 45th registered.
935 studies on the registry are indexed under Delirium; 188 are open to participants now.
Browse Delirium studies →14 of the 78 studies testing dexmedetomidine in Delirium are open now, in 5 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 60+
Tanta University · Sites in Egypt
Ages 21+
Tanta University · Sites in Egypt
Ages 65+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 60+
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.
This study: 1 Month to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 12 · Phase 4 35
First in 2004; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is close to the median of 111 across 551 interventional studies indexed under Delirium.
Median enrollment 98 across the 78 interventional studies. Of the 37 that completed or were terminated, 8 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 78 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Douglas Fraser as lead sponsor.
Douglas Fraser has 1 study filed under Delirium — fewer than ten, so there is no comparison to draw.
3 of the studies testing dexmedetomidine in Delirium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06192615Phase 3Massachusetts General HospitalMinimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS II) | 2027-10-31 |
| NCT04669457University of Massachusetts, WorcesterPediatric Delirium | 2027-04-05 |
| NCT07781462Alexandria UniversityIntravenous Infusion of Low Dose Ketamine Versus Dexmedetomedine for Delirium Treatment in Acute Heart Failure | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 78 studies testing dexmedetomidine in Delirium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
There is a significant lack of adequately powered randomized clinical trial (RCT) data to determine the comparative safety and effectiveness of sedative treatments in pediatric patients. In many centres the standard of care for sedation in pediatric critical care unit (PCCU) patients includes the use of benzodiazepines despite the known negative effects of increased patient agitation and delirium, which can contribute to longer PCCU and hospital length of stay (LOS). The use of an alternative sedative, dexmedetomidine may reduce negative effects in this population. As such, the investigators plan to conduct a well designed comparative RCT to determine the most effective and safest sedative in this vulnerable population utilizing clinical assessments of sedation levels and delirium instance, electroencephalography (EEG) analysis and patient important outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Precedex
Drug: Midazolam
Precedex, dexmedetomidine hydrochloride, IV, 4mcg/mL, infusion duration determined by the clinical care team
Also known as: dexmedetomidine
Midazolam, IV, 5mg/mL (for patients more than 10kg), 1mg/mL (for patients 2-10kg), infusion duration determined by the clinical care team
Target Sedation Range
The percentage of time spent within target sedation range, defined as COMFORT Behaviour Scale score of 11-22, which will be assessed at minimum every 4 hours.
Time frame: Up to 14 days post-randomization
Delirium
Prevalence of delirium using the Cornell Assessment of Pediatric Delirium (CAPD) tool
Time frame: Up to 14 days post-randomization
Delirium
Duration of delirium using the Cornell Assessment of Pediatric Delirium (CAPD) tool
Time frame: Up to 14 days post-randomization
Delirium
Prevalence of delirium using raw and quantitative EEG
Time frame: Up to 14 days post-randomization
Delirium
Duration of delirium using raw and quantitative EEG
Time frame: Up to 14 days post-randomization
Duration of mechanical ventilation
Mechanical ventilation-free days through day 28 will be calculated as 28 minus the duration of mechanical ventilation. Participants who die, are still receiving mechanical ventilation, or are transferred from the PCCU still receiving mechanical ventilation by day 28 will be censored at 28 days and assigned zero mechanical ventilation-free days
Time frame: Up to 28 days post-randomization
PCCU Length of Stay
Length of stay will be calculated from the time of PCCU admission to the time of PCCU discharge.
Time frame: Up to 90 days post-randomization
Hospital Length of Stay
Hospital Length of Stay will be calculated from the time of PCCU admission to the time of physical hospital discharge.
Time frame: Up to 90 days post-randomization
Adverse event (AE) occurrence
Documentation of treatment related adverse events including blood pressure/heart rate changes requiring decreasing or discontinuation of study drug or intervention, delirium requiring medical treatment, any unplanned extubation or line removals, aspirations, ulcerations, etc.determined to result from inadequate sedation
Time frame: Randomization to 90 days post-randomization
Quantification of sleep stages and sleep quality assessment
Visual and automated scoring of sleep stages from EEG recordings Stage 1 sleep: scored when more than 15 seconds of the epoch is made up of theta activity (4to7 Hz) Stage 2 sleep: predominant theta activity (4 to 7 Hz) and occasional quick bursts of faster activity Stage 3/4 sleep: marked by high-amplitude slow waves Rapid eye movement (REM) sleep: characterized by low-amplitude, mixed-frequency theta waves, intermixed with some alpha waves (usually 1 to 2 Hz slower than wake).
Time frame: Up to 14 days post-randomization
Pharmacokinetics - Maximum plasma concentration (Cmax)
Maximum plasma concentration (Cmax)
Time frame: Up to 14 days post-randomization
Pharmacokinetics - Area under the plasma concentration-time curve (AUC)
Area under the plasma concentration-time curve (AUC)
Time frame: Up to 14 days post-randomization
Use of open label boluses for sedation - number
Number of boluses (opioid and benzodiazepine) administered during the treatment period
Time frame: Up to 14 days post-randomization
Use of open label boluses for sedation - total dose
Total dose of boluses (opioid and benzodiazepine) administered during the treatment period
Time frame: Up to 14 days post-randomization
Economic Analysis
The investigators will perform an economic evaluation during this pilot trial. This will be cost estimate analysis based on approximate costs incurred daily in the PCCU. Costs will be determined at discharge from estimated cost per day of admission to the PCCU.
Time frame: Up to 90 days post-randomization
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2021 (actual). Primary completion is estimated for Sep 2024, 39 months after the start.
Of 27 phase 3 interventional studies under Delirium, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 59. This study's planned 39 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexmedetomidine · Midazolam